<DOC>
	<DOCNO>NCT00038896</DOCNO>
	<brief_summary>The primary objective study determine efficacy , safety , tolerability flexible dose venlafaxine extended-release ( ER ) capsule administer 10 week treatment adult outpatient panic disorder ( PD ) placebo-controlled phase III study .</brief_summary>
	<brief_title>Study Evaluating Venlafaxine ER Adults With Panic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>A male female outpatient Be least 18 year age legal age consent Meet DSMIV criterion PD ( without agoraphobia ) least 3 month study day 1 Treatment venlafaxine ( IR ER ) within 6 month study day 1 Known hypersensitivity venlafaxine ( IR ER ) relate compound History presence clinically important hepatic , renal , medical disease might compromise study detrimental patient ( eg , clinically important cardiac arrhythmia , unstable diabetes , carcinoma [ except basal cell epithelioma ] , uncontrolled hypertension )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Panic</keyword>
	<keyword>Disorder</keyword>
</DOC>